Randomisation - stratified by Site, age and PBB

Group: PHID-CV (Intervention)

Group: Menactra (Control)

Clinical review Vaccination Bleed NPS Salivary Swab

Timepoint 1 Day 0

Timepoint 2 Day 6 ±3 days

Timepoint 3 Day 29 ±14 days

Timepoint 4 Day 59 ±14 days

Timepoint 5 7 days post dose 2 ±3

Timepoint 6 29 days post dose 2 ±3

Timepoint 7 182 days post dose 2 ±14 days

Timepoint 8 365 days post dose 2 ±14 days

Solicited Adverse Events

Unsolicited adverse events

Clinical review Bleed NPS Vaccine Salivary Swab

Solicited adverse events

Unsolicited AEs Bleed NPS Salivary Swab

Clinical review Bleed NPS Salivary Swab

Clinical review Bleed NPS Salivary Swab

Respiratory exacerbation surveillance\(^1\)

Serious adverse event monitoring\(^2\)